Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.

IF 2.1 4区医学 Q2 OTORHINOLARYNGOLOGY

Acta Otorhinolaryngologica Italica Pub Date : 2024-10-01 DOI:10.14639/0392-100X-N2827

Xiao-Bin Fu, Ting-Ting Li, Zhao-Dong Fei, Chuan-Ben Chen

{"title":"Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.","authors":"Xiao-Bin Fu, Ting-Ting Li, Zhao-Dong Fei, Chuan-Ben Chen","doi":"10.14639/0392-100X-N2827","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to use the maximum standardised uptake value (SUVmax) of 18F-fluorodeoxyglucose positron emission tomography to improve the cost effectiveness of nimotuzumab (NTZ) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC).Methods: Two hundred and forty-eigh patients with LA-NPC, who met the inclusion criteria, were recruited from January 2012 to June 2019. The survival differences and independent factors were assessed using the Kaplan-Meier method and by Cox proportional hazards regression analysis. A cost effectiveness analysis was performed.Results: The optimal cut-off value for SUVmax was 12.92. Multivariable analysis indicated a prognostic significance of overall survival (OS) for the NTZ treatment (p = 0.023) and SUVmax (p = 0.014). The exploratory subgroup survival analysis revealed that LA-NPC patients with SUVmax > 12.92 treated with concurrent chemoradiotherapy (CCRT) and NTZ had a significantly improved 3-year OS compared to patients treated with CCRT alone (96.2 vs 73.2%, p = 0.047). Furthermore, the treatment cost for NTZ was $6,317.61. This incurred an additional cost of $274.68 for every 1% increase in OS.Conclusions: For patients with LA-NPC with SUVmax > 12.92, the addition of NTZ to CCRT can improve OS and is cost effective.","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":"44 5","pages":"296-305"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556775/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N2827","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aims to use the maximum standardised uptake value (SUV_max) of 18F-fluorodeoxyglucose positron emission tomography to improve the cost effectiveness of nimotuzumab (NTZ) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

Methods: Two hundred and forty-eigh patients with LA-NPC, who met the inclusion criteria, were recruited from January 2012 to June 2019. The survival differences and independent factors were assessed using the Kaplan-Meier method and by Cox proportional hazards regression analysis. A cost effectiveness analysis was performed.

Results: The optimal cut-off value for SUV_max was 12.92. Multivariable analysis indicated a prognostic significance of overall survival (OS) for the NTZ treatment (p = 0.023) and SUV_max (p = 0.014). The exploratory subgroup survival analysis revealed that LA-NPC patients with SUV_max > 12.92 treated with concurrent chemoradiotherapy (CCRT) and NTZ had a significantly improved 3-year OS compared to patients treated with CCRT alone (96.2 vs 73.2%, p = 0.047). Furthermore, the treatment cost for NTZ was $6,317.61. This incurred an additional cost of $274.68 for every 1% increase in OS.

Conclusions: For patients with LA-NPC with SUV_max > 12.92, the addition of NTZ to CCRT can improve OS and is cost effective.

查看原文本刊更多论文

PET/CT 在提高尼莫妥珠单抗治疗鼻咽癌的成本效益方面的作用。

研究目的本研究旨在利用18F-氟脱氧葡萄糖正电子发射断层扫描的最大标准化摄取值（SUVmax）来提高尼莫妥珠单抗（NTZ）治疗局部区域晚期鼻咽癌（LA-NPC）的成本效益：方法：2012年1月至2019年6月期间，招募了248名符合纳入标准的LA-NPC患者。采用 Kaplan-Meier 法和 Cox 比例危险回归分析评估了生存率差异和独立因素。还进行了成本效益分析：SUVmax的最佳临界值为12.92。多变量分析表明，NTZ治疗（p = 0.023）和SUVmax（p = 0.014）对总生存期（OS）具有预后意义。探索性亚组生存分析显示，SUVmax > 12.92的LA-NPC患者接受同期化放疗（CCRT）和NTZ治疗后，其3年生存率显著高于仅接受CCRT治疗的患者（96.2% vs 73.2%，p = 0.047）。此外，NTZ 的治疗费用为 6,317.61 美元。OS每增加1%，额外费用为274.68美元：结论：对于 SUVmax > 12.92 的 LA-NPC 患者，在 CCRT 治疗的基础上加用 NTZ 可以改善 OS，并且具有成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Otorhinolaryngologica Italica OTORHINOLARYNGOLOGY-

CiteScore

3.40

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini. It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.). The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief. Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.